Skip to content
Boca Raton City Online – Lifestyle
Author:
Unicycive Therapeutics, Inc.
Unicycive Therapeutics Appoints Meredith Manning to Board of Directors
October 1, 2026
Unicycive Therapeutics Announces Resubmission of New Drug Application for Oxylanthanum Carbonate
September 29, 2026
Unicycive Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference
September 1, 2026
Unicycive Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update
August 12, 2026
Lilly’s triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C
July 23, 2026
Unicycive Therapeutics Receives Complete Response Letter from FDA Regarding Resubmitted Oxylanthanum Carbonate (OLC) New Drug Application (NDA)
June 30, 2026
What Medicare Part D patients need to know about accessing Foundayo (orforglipron) and Zepbound (tirzepatide) for weight management
June 25, 2026
Zepbound (tirzepatide) and Shaquille O’Neal launch national campaign after NBA legend learns the obstructive sleep apnea he has lived with for years is treatable
June 10, 2026
Lilly’s oral GLP-1 Foundayo (orforglipron) delivered superior A1C control and weight loss in three pivotal type 2 diabetes trials
June 9, 2026
Lilly’s triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity and its complications
June 8, 2026
1
2
3
Next Page
→